Motif Bio Appoints Scientific Opinion Leaders to Advisory Board

10 May 2017

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced the appointment of Dr.Thomas Lodise, Dr.Thomas Holland and Dr.William O’Riordan to the Clinical Advisory Board.

The three new advisory board members are medical and scientific leaders in their fields:

Thomas Lodise, Pharm.D., Ph.D. is a Professor at Albany College of Pharmacy and Health Sciences, Albany, New York and an infectious diseases clinical pharmacy specialist at the Stratton VA Medical Center, Albany, New York. His specific research objectives are to develop “personalised” patient care strategies that improve outcomes; reduce the likelihood of drug-induced toxicities; minimize the emergence of antibiotic resistant infections; and reduce healthcare costs.  He has published over 110 peer-reviewed articles and is an editorial board member for Antimicrobial Agents and ChemotherapyPharmacotherapy, and Diagnostic Microbiology and Infectious Diseases.  He is the current chair of the PK Special Emphasis Panel for the Antibacterial Resistance Leadership Group (ARLG), an initiative funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).

 Thomas L. Holland, MD, MSc-GH is an Assistant Professor at Duke University School of Medicine. Board certified in infectious disease, Dr Holland has held a number of clinical positions at Duke University School of Medicine and is currently Assistant Professor in the Department of Infectious Diseases. With over 30 publications, Dr Holland is an expert in antibacterial resistance with a focus on Gram-positive bacteria and is a member of ARLG.

William D. O’Riordan, MD is the founder and CEO of eStudy Sites, one of the pre-eminent network of clinical trial sites in the U.S. He is certified with the American Board of Emergency Medicine and is the lead investigator at the Chula Vista Research Site in California.  Dr. O’Riordan has held a number of clinical positions at the UCLA (University of California, Los Angeles) Medical Center and works at the Department of Emergency Medicine at the Sharp Chula Vista Medical Center. As a clinical trial Investigator at the eStudy Site at the Chula Vista Research Site, he has overseen numerous clinical trials with antibacterial agents at all stages of clinical development.

Dr. David Huang, CMO of Motif Bio commented: “We are delighted to welcome these three outstanding scientific leaders to our Clinical Advisory Board. Each of them brings specific expertise that will be invaluable as we develop and prepare to commercialise iclaprim for patients with serious and life-threatening infections.”


For further information please contact:

Motif Bio plc

Graham Lumsden (Chief Executive Officer)



Dr. Christopher Golden/ Oliver Jackson


+44 (0)20 7418 8900
Northland Capital Partners Limited (BROKER)

Patrick Claridge/ David Hignell

John Howes/ Rob Rees (Broking)


+44 (0)20 3861 6625
Walbrook PR Ltd. (FINANCIAL PR & IR)

Paul McManus

Mike Wort


+44 (0)20 7933 8780 or

Mob: +44 (0)7980 541 893

Mob: +44 (0)7900 608 002

Raimund Gabriel +49 (0)89 210 2280


About Motif Bio plc


Notes to Editors:

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.


This information is provided by RNS

The company news service from the London Stock Exchange